What is Exscalate

At Exscalate we are transforming the drug discovery process. The use of supercomputing and AI enhances and accelerates what is a highly complex process. Collaborating with our partners in an open innovation approach, the Exscalate platform boosts preclinical and clinical candidate selection as well as supporting new drug design and drug repurposing strategies. 

Exscalate is the result of vast expertise. Leveraging significant drug development capabilities together with more than 20 years experience Dompé, in collaboration with Cineca and the Polytechnic University of Milan, developed the Exscalate platform, which is supported by a worldwide network of over 60 partners. From the worlds of supercomputing, AI, chemistry and biology, all these partners bring unique capabilities that have resulted in what is a transformational platform. 

Exscalate platform 

The Exscalate platform is composed of three complementary modules: a Tangible Chemical Space, which includes the largest enumerated chemical library in the world, a Comprehensive Therapeutic Target Database (CTTD) and a powerful in-silco simulator - LiGen. Harnessing the capabilities of supercomputing, these modules together deliver a platform of not only unprecedented speed but of the highest quality and scalability. 
The Exscalate platform has helped boost the identification of drug candidates for multiple validated targets, including some ongoing late-stage clinical trials in disease areas such as viral infection, ophthalmology, oncology and immune disease.

Partnerships

Through an open innovation approach, we help our partners get novel molecules for the most challenging targets through to the clinical stages. Whether it is academic institutions, government organizations, research networks, start-ups, biotech spin-offs or established industry players we collaborate with partners to accelerate drug discovery programs. We help drive results. These results are evident from our pipeline of projects, which are either co-developed with another life sciences company, wholly owned or a collaboration with an academic institution or research network. 

Solutions

Pioneering new cures to complex diseases is a goal we are all working towards. Our platform has the capabilities for our partners to reach that goal. Discover what value it can unlock for you whether you’re a start-up biotech, an established player in the pharma industry or an academic researcher. 

“We have developed the world’s first human extracellular matrix (ECM)-based drug discovery platform. The ECM is a key component of human tissues constantly remodelled during disease progression and it acts as common denominator between fibrosis and solid tumours. The use of tissue- and disease-specific human ECM platform is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Exscalate accelerates the pre-clinical and clinical translation of identified targets, helping us not only to quickly identifying hits and candidates molecules for drug discovery and development but to promptly address potential tox risks and off-target selectivity through artificial intelligence and ultra-high performance supercomputing. This strategic partnership is a great example of how the combination of two technology platforms, our human ECM and Exscalate, together with our joint teams’ insights and co-operation, can accelerate research that will bring new therapeutic solutions to unmet patient needs."

Giuseppe Mazza, Chief Executive Officer and Co-Founder of Engitix

"Dompé’s Exscalate platform rapidly accelerated the timeline from target identification to IND for our lead compound A197, a novel immunomodulatory agent. In just 14 months, we received FDA acceptance of our IND application for a new molecular entity (NME) and are now enrolling subjects in a robust Phase 2 clinical trial."

Reza Dana, MD, MPH, MSc - Scientific Co-Founder of Aramis Biosciences and faculty member at Massachusetts Eye and Ear, Harvard Medical School, Boston.

“We have developed the world’s first human extracellular matrix (ECM)-based drug discovery platform. The ECM is a key component of human tissues constantly remodelled during disease progression and it acts as common denominator between fibrosis and solid tumours. The use of tissue- and disease-specific human ECM platform is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Exscalate accelerates the pre-clinical and clinical translation of identified targets, helping us not only to quickly identifying hits and candidates molecules for drug discovery and development but to promptly address potential tox risks and off-target selectivity through artificial intelligence and ultra-high performance supercomputing. This strategic partnership is a great example of how the combination of two technology platforms, our human ECM and Exscalate, together with our joint teams’ insights and co-operation, can accelerate research that will bring new therapeutic solutions to unmet patient needs."

Giuseppe Mazza, Chief Executive Officer and Co-Founder of Engitix

"Dompé’s Exscalate platform rapidly accelerated the timeline from target identification to IND for our lead compound A197, a novel immunomodulatory agent. In just 14 months, we received FDA acceptance of our IND application for a new molecular entity (NME) and are now enrolling subjects in a robust Phase 2 clinical trial."

Reza Dana, MD, MPH, MSc - Scientific Co-Founder of Aramis Biosciences and faculty member at Massachusetts Eye and Ear, Harvard Medical School, Boston.

“We have developed the world’s first human extracellular matrix (ECM)-based drug discovery platform. The ECM is a key component of human tissues constantly remodelled during disease progression and it acts as common denominator between fibrosis and solid tumours. The use of tissue- and disease-specific human ECM platform is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Exscalate accelerates the pre-clinical and clinical translation of identified targets, helping us not only to quickly identifying hits and candidates molecules for drug discovery and development but to promptly address potential tox risks and off-target selectivity through artificial intelligence and ultra-high performance supercomputing. This strategic partnership is a great example of how the combination of two technology platforms, our human ECM and Exscalate, together with our joint teams’ insights and co-operation, can accelerate research that will bring new therapeutic solutions to unmet patient needs."

Giuseppe Mazza, Chief Executive Officer and Co-Founder of Engitix

Institutional Endorsement

Ursula von der Leyen, President of the European Commission, discusses how partners in the EU-funded project - Exscalate4Cov - came together in the fight against COVID-19.

During the inauguration of the Exscalate offices at Napoli’s Federico II University, Roberto Viola, Director General of DG CONNECT European Commission, discusses the success of the Exscalate4Cov project in bringing together a multidisciplinary team of partners that leveraged European supercomputing resources and the Exscalate platform to allow for the rapid discovery of a promising drug for COVID-19 patients.